GSK keeps its financial reporting under regular review to ensure that it remains current and in line with both the latest regulatory requirements and developing best practice within the Pharmaceutical industry. Consumer Healthcare product sales categories updated Following the closing of the transaction that combined the assets of the legacy GSK Consumer Healthcare business with Pfizer consumer healthcare on 31 July 2019, GSK completed a review of the segment sales disclosures applicable to the new Consumer Healthcare Joint Venture business. A revised and more detailed disclosure of category sales will provide greater transparency to the main drivers of the Consumer Healthcare Joint Venture's performance. Previously reported Nutrition and Skin health categories will no longer be used as a result of GSK's focus in the portfolio on core categories via targeted divestments. Nutrition, Skin health and the category previously called "Wellness" will be replaced by four more specific categories structured around GSK's global power brand1 portfolio and closely aligned to consumer healthcare industry standard definitions: · Oral health (unchanged) includes the power brands Sensodyne, Parodontax and the Denture care franchise comprising approximately 85%2 of category sales. GSK leads the therapeutic Oral health segment globally3. · Pain relief includes the power brands Voltaren, Panadol and Advil comprising 86%2 of category sales with an additional 11% of sales from leading regional brands ('local stars'). GSK holds the global #1 position in this category4. · Respiratory health includes cold & flu, allergy and cough brands. Combined power brands (Theraflu and Otrivin) and 'local star' brands comprise over 70%2 of category sales. GSK holds the global #1 position in this category4. · Vitamins, minerals and supplements includes power brand Centrum and 'local stars' Caltrate and Emergen-C as well as smaller brands that were previously reported in the Nutrition category. Power brands and 'local stars' comprise over 70%2 of category sales and GSK holds the global #1 position in this category4. · Digestive health and other includes 'local star' Digestive health brands Tums, Nexium and Eno; the OTC Smokers' health franchise; small dermatology brands previously reported in Skin health; and any other products not reported elsewhere. · Brands divested and under review includes those brands that have been divested but remain in the comparative sales disclosures for 2019 and earlier years; previously announced divestments including the sale of the Horlicks and other family nutrition brands in India and certain other markets to Hindustan Unilever Ltd; and brands under review as part of the divestment programme announced at the time of the formation of the joint venture with Pfizer. The revised Consumer Healthcare turnover tables below set out the new format for reporting Consumer Healthcare product sales that will be used beginning with the Q1 2020 Results Announcement and applied to the 2019 reported and pro forma Consumer Healthcare product sales. An Excel version of this data is available on www.gsk.com. ___________________________________________________________________________ 1 GSK Consumer Healthcare has a portfolio of nine global power brands and fifteen leading regional ('local star') brands comprising over 70%2 of total sales excluding brands divested and under review. 2 Percentages are estimated based on 2019 sales of legacy GSK and Pfizer consumer healthcare brands. 3 GSK analysis based on Nielsen, IRI and Euromonitor data. 4 Nicholas Hall's DB6 Consumer Healthcare database 2018. |